Biotechnology

Precigen

Precigen released FY2026 Q1 earnings on May 13 After-Market EST, actual revenue USD 23.25 M (forecast USD 20.8 M), actual EPS USD -0.0223 (forecast USD -0.04)

Precigen to Release FY2026 Q1 Earnings on May 13 After-Market (EST), Forecast Revenue USD 20.8M, EPS USD -0.04

Precigen released FY2025 Q4 earnings on March 25 After-Market (EST), actual revenue USD 4.565 M (forecast USD 8.286 M), actual EPS USD -0.0663 (forecast USD -0.084)

Precigen released FY2025 earnings on March 25 After-Market EST, actual revenue USD 9.684 M (forecast USD 13.53 M), actual EPS USD -1.3727 (forecast USD -0.8774)

Precigen to Release FY2025 Earnings on March 25 After-Market (EST), Forecast Revenue USD 13.53 M, EPS USD -0.8774

Randal J. Kirk Sells Precigen Inc. Shares

Jeffrey B. Kindler Sells Ordinary Shares of Precigen Inc.

Precigen released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 5.119 M, actual EPS USD -1.3333

Precigen released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 2.922 M (forecast USD 500 K), actual EPS USD -1.0599 (forecast USD -0.095)

Precigen to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 666.67K, EPS USD -0.0933

Precigen's PAPZIMEOS Receives FDA Approval for RRP Treatment

Analyst Gives Precigen Strong Buy Rating

FDA Approves Precigen's Papzimeos for RRP

Precigen Inc. Director Acquires Company Shares

JMP Securities Raises Precigen's Target Price to $8

Precigen released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 856K (forecast USD 666.67K), actual EPS USD -0.0899 (forecast USD -0.0833)

Precigen released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 2.197 M, actual EPS USD -0.2737

JPMorgan Maintains Outperform Rating on Precigen

Cantor Fitzgerald Reiterates Precigen Buy Rating

Precigen released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 1.341 M (forecast USD 500 K), actual EPS USD -0.1842 (forecast USD -0.08)

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

MicroAlgo

Tradr 2X Long XNDU Daily ETF

PGEN

SBIO

IBBQ

LABU

Precigen, Inc. reported Q1 2026 revenue of $23.25 million, up from $1.34 million a year prior, with a reduced net loss of $7.93 million. The growth was driven by PAPZIMEOS sales, generating $21.6 million. The company aims for cash flow breakeven by 2026, but faces risks from reliance on PAPZIMEOS. Analysts project significant revenue growth, with a fair value estimate of $8.50, indicating a 92% upside. Investor sentiment varies widely, highlighting the importance of evaluating different growth scenarios.

Simplywall

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

How Surging PAPZIMEOS Revenue And Narrower Losses At Precigen (PGEN) Have Changed Its Investment Story

BNGO

Bionano Genomics (NASDAQ:BNGO) reported Q1 2026 revenue of $6.7 million, a 4% year-over-year increase, with flow cell sales up 17%. The company highlighted strategic pillars focused on supporting its installed base, increasing Optical Genome Mapping (OGM) utilization, securing reimbursement, and improving profitability. Key milestones include a 47% increase in reimbursement rates for OGM and a new CPT code for genetic disorders. Gross margin improved to 49%, and the company aims for cash flow breakeven by Q4 2027, driven by strong demand and reduced debt.

Fidelity

Bionano Genomics

iShares US Medical Devices

Transcript: Bionano Genomics Q1 2026 Earnings Conference Call

Precigen shares are trading higher after the company reported Q1 sales results.

benzinga_article

Earnings Watch

Precigen | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 23.25 M

XTNT

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

StockTitan

Xtant Med

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

Today, in Germantown, Maryland, Precigen, Inc. (Nasdaq: PGEN), a company focused on developing cutting-edge precision medicines to enhance patient well-being, revealed its plans to unveil the results of its first quarter in 2026.

Unusual Whales

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

UPST

MNTN

UXIN

The U.S. market has seen a 29% drop in the past week and an 82% decline over the year. Amidst this, growth companies with high insider ownership are appealing. Notable companies include Uxin (35.6% ownership), Upstart Holdings (13%), and Precigen (11.9%). Marqeta, MNTN, and Workiva are highlighted for their growth potential and insider ownership of 12.5%, 12.5%, and 10.3%, respectively. Each company shows promising revenue growth and strategic developments, although some may be trading above their estimated value. This analysis is based on historical data and does not constitute financial advice.

Upstart

Workiva

Marqeta

Uxin

Karman

Enovix

Clene

Caledonia Mining

Better Home & Finance

Astera Labs

AppLovin

NASDAQ Composite Index

CLENE INC C/WTS 30/12/2025 (TO PUR COM)

BETTER HOME & FINANCE HOLDING C/WTS 22/08/2028(TO PUR COM)

3 Growth Companies With Insider Ownership Up To 12%

Precigen (PGEN) has gained attention following FDA approval for PAPZIMEOS, with sales starting and a new CMS J-code effective April 2026. The stock price is currently $4.17, reflecting an 18.8% return over the past month. Analysts suggest a fair value of $8.50 per share, indicating potential undervaluation. However, Precigen's high P/B ratio of 70.6 raises concerns about whether the premium is justified. The narrative emphasizes the need for sustained momentum in sales and manageable financing to support growth expectations.

A Look At Precigen (PGEN) Valuation As PAPZIMEOS Commercial Launch And J Code Spark Investor Interest

Precigen(PGEN.US)

How Surging PAPZIMEOS Revenue And Narrower Losses At Precigen (PGEN) Have Changed Its Investment Story

Transcript: Bionano Genomics Q1 2026 Earnings Conference Call

Precigen shares are trading higher after the company reported Q1 sales results.

Precigen | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 23.25 M

Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

3 Growth Companies With Insider Ownership Up To 12%

A Look At Precigen (PGEN) Valuation As PAPZIMEOS Commercial Launch And J Code Spark Investor Interest